Literature DB >> 19231017

Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice.

Pietro Lampertico.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19231017     DOI： 10.1016/j.jhep.2009.01.007

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  9 in total

1.  Prolonged entecavir therapy is not effective for HBeAg seroconversion in treatment-naive chronic hepatitis B patients with a partial virological response.

Authors:  Hyun Woong Lee; Jae-Cheol Kwon; In Soo Oh; Hye Young Chang; Young Joo Cha; Ik-Seong Choi; Hyung Joon Kim
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

2.  Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir.

Authors:  Hana Park; Jun Yong Park; Seung Up Kim; Do Young Kim; Kwang-Hyub Han; Chae Yoon Chon; Sang Hoon Ahn
Journal:  World J Gastroenterol       Date:  2013       Impact factor: 5.742

3.  Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir.

Authors:  Han Na Choi; Jeong Eun Song; Hyeon Chul Lee; Hyeong Ho Jo; Chang Hyeong Lee; Byung Seok Kim
Journal:  Clin Mol Hepatol       Date:  2015-03-25

4.  Virologic response and safety of tenofovir versus entecavir in treatment-naïve chronic Hepatitis B patients.

Authors:  Hyung Min Yu; So Young Kwon; Jiwan Kim; Hyun Ah Chung; Se Woong Kwon; Taek Gun Jeong; Sang Hee An; Gyung Won Jeong; Seon Ung Yun; Jae Ki Min; Jeong Han Kim; Won Hyeok Choe
Journal:  Saudi J Gastroenterol       Date:  2015 May-Jun       Impact factor: 2.485

5.  Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life.

Authors:  Jie Luo; Xiangyong Li; Yuankai Wu; Guoli Lin; Yihua Pang; Xiao Zhang; Yunlong Ao; Zhan Du; Zhixin Zhao; Yutian Chong
Journal:  Int J Med Sci       Date:  2013-03-01       Impact factor: 3.738

6.  Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine Therapy.

Authors:  Bin Zhou; Hui Dong; Yungang He; Jian Sun; Weirong Jin; Qing Xie; Rong Fan; Minxian Wang; Ran Li; Yangyi Chen; Shaoqing Xie; Yan Shen; Xin Huang; Shengyue Wang; Fengming Lu; Jidong Jia; Hui Zhuang; Stephen Locarnini; Guo-Ping Zhao; Li Jin; Jinlin Hou
Journal:  Sci Rep       Date:  2015-11-24       Impact factor: 4.379

7.  The Efficacy of Add-on Telbivudine Versus Switching to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients With Poor Responses to Adefovir.

Authors:  Xin Wei; Chao Fan; Yun Zhou; Wenzhen Kang; Jiuping Wang; Li Sun; Linxu Wang; Meijuan Peng; Jianqi Lian; Zhansheng Jia; Chunqiu Hao
Journal:  Hepat Mon       Date:  2016-01-23       Impact factor: 0.660

8.  Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.

Authors:  Jung Gil Park; Soo Young Park
Journal:  Clin Mol Hepatol       Date:  2015-09-30

9.  Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response.

Authors:  Hyun Young Woo; Jun Yong Park; Si Hyun Bae; Chang Wook Kim; Jae Young Jang; Won Young Tak; Dong Joon Kim; In Hee Kim; Jeong Heo; Sang Hoon Ahn
Journal:  Clin Mol Hepatol       Date:  2020-05-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.